Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Medclair AB should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Medclair AB for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Medclair AB
123.58%
2.92
52.53%
OMX Stockholm 30
8.01%
0.24
18.06%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
40.47%
EBIT Growth (5y)
42.80%
EBIT to Interest (avg)
-2.41
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.07
Sales to Capital Employed (avg)
0.76
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0.44%
ROE (avg)
3.56%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
Industry P/E
Price to Book Value
NA
EV to EBIT
-0.25
EV to EBITDA
-0.12
EV to Capital Employed
-0.02
EV to Sales
-0.03
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
7.62%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bearish
Mildly Bearish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend23What is working for the Company
PRE-TAX PROFIT(Q)
At SEK 3.95 MM has Grown at 2,383.82%
NET PROFIT(Q)
At SEK 3.95 MM has Grown at 2,383.82%
ROCE(HY)
Highest at 11.02%
RAW MATERIAL COST(Y)
Fallen by -743.61% (YoY
DEBT-EQUITY RATIO
(HY)
Lowest at -6.72 %
NET SALES(Q)
Highest at SEK 15.63 MM
OPERATING PROFIT(Q)
Highest at SEK 5.58 MM
OPERATING PROFIT MARGIN(Q)
Highest at 35.69 %
-3What is not working for the Company
NET SALES(9M)
At SEK 26.75 MM has Grown at -22.41%
Here's what is working for Medclair AB
Pre-Tax Profit
At SEK 3.95 MM has Grown at 2,383.82%
Year on Year (YoY)MOJO Watch
Near term Pre-Tax Profit trend is very positive
Pre-Tax Profit (SEK MM)
Net Profit
At SEK 3.95 MM has Grown at 2,383.82%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is very positive
Net Profit (SEK MM)
Net Sales
Highest at SEK 15.63 MM
in the last five periodsMOJO Watch
Near term sales trend is positive
Net Sales (SEK MM)
Operating Profit
Highest at SEK 5.58 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (SEK MM)
Operating Profit Margin
Highest at 35.69 %
in the last five periodsMOJO Watch
Company's profit margin has improved
Operating Profit to Sales
Debt-Equity Ratio
Lowest at -6.72 %
in the last five Semi-Annual periodsMOJO Watch
The company has been reducing its borrowing as compared to equity capital
Debt-Equity Ratio
Raw Material Cost
Fallen by -743.61% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
